Publications by authors named "Mary Ruisi"

Claim this Profile
V
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial.
Thomas Louie, Yoav Golan, Sahil Khanna, Dmitri Bobilev, Nathalie Erpelding, Mary Ruisi

JAMA· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial.
David M Loeb, Ji Won Lee, Daniel A Morgenstern, Yvan Samson, Anne Uyttebroeck, Mary Ruisi

Cancer Immunol Immunother· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab Dose Selection for Clinical Studies in Pediatric Patients with Solid Tumors.
Yulia Vugmeyster, Ana-Marija Grisic, Brigitte Brockhaus, Peter Rueckert, Mary Ruisi

Clin Pharmacokinet· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term avelumab in advanced non-small-cell lung cancer: summaries and analyses from JAVELIN Solid Tumor.
Borys Hrinczenko, Nicholas Iannotti, Sanjay Goel, David Spigel, Howard Safran, Mary Ruisi

Future Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab.
Nadia Terranova, Jonathan French, Haiqing Dai, Matthew Wiens, Akash Khandelwal, Mary Ruisi

CPT Pharmacometrics Syst Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer.
Xinke Zhang, Richard W DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Mary Ruisi

Immunotherapy· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David Spigel, James C H Yang, Mary Ruisi

J Thorac Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced expression of annexin A2 is associated with impaired cell surface fibrinolysis and venous thromboembolism.
Hannah Fassel, Huigen Chen, Mary Ruisi, Neha Kumar, Maria DeSancho

Blood· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
Keunchil Park, Mustafa Özgüroğlu, Johan Vansteenkiste, David Spigel, James C-H Yang, Mary Ruisi

Lung Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
Andrea B Apolo, John A Ellerton, Jeffrey R Infante, Manish Agrawal, Michael S Gordon, Mary Ruisi

J Immunother Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
Hans Juergen Grote, Zheng Feng, Michael Schlichting, Christoph Helwig, Mary Ruisi

J Thorac Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Fabrice Barlesi, Johan Vansteenkiste, David Spigel, Hidenobu Ishii, Marina Garassino, Mary Ruisi

Lancet Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Sandra P D'Angelo, James Larkin, Jeffrey A Sosman, Celeste Lebbé, Benjamin Brady, Mary Ruisi

J Clin Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Jeffrey S Weber, Geoff Gibney, Ryan J Sullivan, Jeffrey A Sosman, Craig L Slingluff, Mary Ruisi

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A. Davies, Gennaro Ciliberto, Mary Ruisi

J Transl Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series.
Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke

J Immunother Cancer· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia.
Sarah J Barsam, Bethan Psaila, Marc Forestier, Lemke K Page, Peter A Sloane, Mary M Ruisi

Blood· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stability of measurement of the immature platelet fraction.
Mary M Ruisi, Bethan Psaila, Mary J Ward, Glynnis Villarica, James B Bussel

Am J Hematol· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis